CANTA.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$400000	-99.8%	$-0.63	$-0.63–$-0.63	—	1
2027	$3M	+525.0%	$-0.64	$-0.64–$-0.64	—	1
2028	$158M	+6200.0%	$-0.69	$-0.69–$-0.69	—	1
2029	$263M	+66.7%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 4 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-19	$-0.17	$-0.13	+23.5%
2026-05-19	$-0.18	$-0.13	+27.8%
2026-02-20	$-0.19	$-0.13	+31.6%
2025-11-19	$-0.18	$1.07	+694.4%

DCF fair valuemodel estimate

Intrinsic value

$19.91

Price

$1.57

Implied upside

+1167%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CANTA.STCantargia AB (publ)	$1.56	-1.27%	$440M	—
ADDV-B.STADDvise Group AB (publ)	$1.73	+0.58%	$1.0B	—
IBT-B.STInfant Bacterial Therapeutics AB (publ)	$65.90	-0.15%	$858M	—
IMMU.STMendus AB (publ)	$6.50	-2.11%	$398M	—
ITECH.STI-Tech AB	$74.40

Cantargia AB (publ)

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.

www.cantargia.com

Employees: 22
IPO / List date: Mar 17, 2015
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds CANTA.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in CANTA.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CANTA.ST yet.